Skip to main content
. 2023 Aug 6;9(8):e18967. doi: 10.1016/j.heliyon.2023.e18967

Table 1.

Patient characteristics (N = 84).

Characteristic Value
Sex, n (%)
 Male 32 (38.1)
 Female 52 (61.9)
Diagnostic method, n (%)
 Bronchoscopy 60 (71.4)
 Sputum 24 (28.6)
Radiographic features, n (%)
 NB type 78 (92.9)
 FC type 6 (7.1)
 Age (years), mean ± SD 66.8 ± 10.4
 Body mass index (kg/m2), median ± SD 19.7 ± 2.6
 Smoking status Current + former smoker, n (%) 32 (38.0)
Underlying disease, n (%)
 Cancer 25 (29.8)
 Tuberculosis 8 (9.5)
 COPD 7 (8.3)
 Diabetes mellitus 7 (8.3)
 Sinusitis 6 (7.1)
 Collagen disease 11 (13.1)
 Use of immunosuppressant, n (%) 15 (17.9)
Blood tests
 White blood cells (/μL), mean ± SD 6092.8 ± 2181.7
 Neutrophil, mean ± SD 4061.1 ± 2056.0
 C reactive protein (mg/dL), mean ± SD 0.5 ± 1.7
 KL-6 (IU/L), mean ± SD 300.7 ± 177.1
 Alb (g/dL), mean ± SD 4.1 ± 0.4
 Anti-GPL-core IgA antibody positive, n (%) 36 (64.3)
 IGRA positive, n (%) 6 (12.2)
Pulmonary function
 VC (L), mean ± SD 3.4 ± 3.0
 %VC (%), mean ± SD 100.7 ± 14.7
 FVC (L), mean ± SD 2.8 ± 2.6
 %FVC (%), mean ± SD 99.1 ± 14.2
 FEV1 (L), mean ± SD 2.0 ± 0.5
 %FEV1 (%), mean ± SD 101.2 ± 20.2
 FEV1% (G) (%), mean ± SD 74.6 ± 10.9
 Peak Flow (L/min), mean ± SD 5.7 ± 1.5
 DLCO (mL/min/mmHg), mean ± SD 19.1 ± 17.7
 DLCO/VA (mL/min/mmHg/L), mean ± SD 6.6 ± 12.9
Species isolated, n (%)
 Mycobacterium avium 66 (78.6)
 Mycobacterium intracellulare 17 (20.2)
 Unidentified species 1 (1.2)
 Treatment with a macrolide-containing multidrug regimen, n (%) 43 (51.2)

Alb, albumin; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity for carbon monoxide; FC, fibrocavitary; FEV1, forced expiratory volume in 1 s; FEV1%(G), Gänsler's FEV1% (= FEV1/VC x 100); FVC, forced vital capacity; GPL, glycopeptidolipid; IGRA, interferon-gamma release assay; KL-6, Krebs von den Lungen; NB, nodular/bronchiectasis; SD, standard deviation; VA, alveolar ventilation; VC, vital capacity.